Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leucovorin is a chemically reduced derivative of folic acid and acts as an active metabolite (folinic acid). It is classified as a folic acid analog and functions primarily to protect healthy cells from the toxic effects of methotrexate and other folic acid antagonists by bypassing the inhibition of dihydrofolate reductase. This allows nucleic acid synthesis to proceed even in the presence of methotrexate. Leucovorin is also used to enhance the efficacy of fluorouracil in colorectal cancer by stabilizing the binding of its active metabolite (5-FdUMP) to thymidylate synthetase. Additionally, it can be used for treating certain types of anemia caused by low levels of folic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leucovorin.